Neutralizing elevated TFF3 to reduce SRC/STAT3 activation and PTGS2 induction or blocking the interaction between TFF3 and its receptor, CD147, may be a promising strategy for the chemoprevention and treatment of CRC. Here, STAT3 is linked to colorectal carcinoma.